TEL AVIV, Israel, May 9, 2017 /PRNewswire/ -- 2breathe Technologies Ltd. with its wholly owned U.S. subsidiary Resperate Inc. announced that a new review article, titled "The Role of Paced Breathing for Treatment of Hypertension" recommends RESPeRATE for newly diagnosed hypertensives, and for patients who are not controlled or unable to tolerate the adverse effects of prescribed medications. Scheduled for publication in the June issue of Current Hypertension Reports, the review further recommends that physicians consider using RESPeRATE as a means to reducing the number of medications in well controlled patients.
The article, led by Dr. R. Cernes from the Brunner Institute for Cardiovascular Research, Tel Aviv University and Wolfson Medical Center, Holon, Israel, further solidifies the 2013 American Heart Association's scientific statement that recommends RESPeRATE as a treatment for hypertension and the only product recommendation in the new device/guided breathing category.
The article discusses the antihypertensive effect of slow and deep respirations via increasing baroreflex sensitivity, and decreasing sympathetic neural activity. It then summarizes published RESPeRATE clinical studies and review papers as well as the latest studies from Yoga, Transcendental Meditation, Bi-Level Positive Pressure Device and other devices.
"Paced breathing plays an important role in behavioral methods of treating hypertension and has a direct physiological effect on blood pressure, especially when prolonging exhalation," said Dr. Cernes. "However, slow paced breathing can often be unworkable, requiring patients to perform them without assistance. Apart from the prolonged training, practice, skill and motivation needed, being able to perform paced breathing without conscious effort involves individualized breathing patterns that typically require personal coaching.
The FDA-cleared RESPeRATE's device uses guided breathing technology to help patients perform daily paced breathing exercises easily and at their convenience, as demonstrated in multiple studies reviewed in the article."
"We are delighted to see RESPeRATE and the benefits of paced breathing gain industry recognition as an accepted part of hypertension therapy," said Erez Gavish, co-founder/CEO of 2breathe Technologies. "The 250,000 RESPeRATE users continue to demonstrate how new digital therapeutic technology can deliver the ancient wisdom of slow paced breathing in a practical, effective way for anyone and in the home setting."
Elevated blood pressure or hypertension is a major risk factor for adverse cardiovascular events, including myocardial infarction, stroke, heart failure, and death. Hypertension affects 4 out of 10 of adults worldwide. The need for safe and effective novel hypertension treatments exists as 20% or more of the patients with hypertension do not achieve the target BP of <140/90 mmHg, even after the implementation of good large scale hypertension programs of antihypertensive drug therapy and lifestyle modification.
Current Hypertension Reports provides in-depth review articles contributed by international experts on the most significant developments in the field.
About 2breathe Technologies Ltd.
Tel Aviv-based 2breathe Technologies Ltd. and its wholly owned U.S. subsidiary Resperate Inc. is a pioneer of digital therapeutic devices in the areas of hypertension and sleeplessness. The company's RESPeRATE®: Hypertension Therapy is the first FDA-cleared, non-pharmacological hypertension treatment device currently used by hundreds of thousands of patients worldwide. Its 2breathe: Sleep Inducer™product, a winner of the 2017 CES Innovation award, adopts RESPeRATE'S real-time coach guided-breathing technology to induce sleep.
For additional information about 2breathe Technologies, its technology and products please visit http://www.resperate.com/hypertension
Co-Founder & CEO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-review-article-highlights-the-role-of-paced-breathing-and-resperate-for-treatment-of-hypertension-300454235.html
SOURCE 2breathe Technologies Ltd